| Market Cap | 422.86M-31.1% |
| Revenue (ttm) | 0 |
| Net Income | -2.97M |
| EPS | -0.04 |
| Shares Out | 70.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 206,967 |
| Open | 7.01 |
| Previous Close | 7.18 |
| Day's Range | 5.87 - 7.45 |
| 52-Week Range | 1.70 - 15.72 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
3 qualifying trades · 1 insider · $128.53K bought in the last 90 days
YD Bio Ltd Stock Analysis — InsiderScore
See top-rated InsiderScore stocks ›YD Bio Ltd scored higher than 9% of companies evaluated by InsiderBuying, and ranked 70th out of 95 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at YD Bio Ltd bought $128.5K of stock across 3 purchases in the last 90 days, the largest of them $67.4K.
The average purchase added about 0% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
About YDES
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Ask Barron about YDES
$YDES stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in YDES holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by YDES's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
YDES Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New YDES patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to YDES from public contracts
Source: USAspending.gov
YDES Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from YDES’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: ranks #70 of 95 scored Biotech stocks · sector average 60.6
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+19.0 since Sep 11Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.